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David E. Winchester, MD,* Xuerong Wen, MPH,† William D. Brearley, MD,* Ki E. Park, MD,*
R. David Anderson, MD,* Anthony A. Bavry, MD, MPH*
Gainesville, Florida
Objectives The purpose of this study was to investigate the efficacy and safety of glycoprotein IIb/IIIa inhibitors (GPIs) dur-
ing elective percutaneous coronary intervention (PCI).
Background Studies have documented that GPIs are useful during PCI; however, much of this research was conducted before
the routine use of coronary stents and thienopyridines.
Methods We searched the MEDLINE, Cochrane clinical trials, and ClinicalTrials.gov databases from inception for studies
that randomly assigned patients undergoing elective PCI to a GPI versus control. Trials were included if stents
and thienopyridines were used routinely and clinical outcomes were reported. Outcomes were assessed within
30 days. A DerSimonian-Laird model was used to construct random effects summary risk ratios (RRs) and 95%
confidence intervals (CIs).
Results Our search yielded 22 studies with 10,123 patients. The incidence of nonfatal myocardial infarction was 5.1% with
GPI versus 8.3% with control (RR: 0.66, 95% CI: 0.55 to 0.79, p  0.0001). Major bleeding was 1.2% versus 0.9%
(RR: 1.37, 95% CI: 0.83 to 2.25, p  0.22), minor bleeding was 3.0% versus 1.7% (RR: 1.70, 95% CI: 1.28
to 2.26, p  0.0001), and mortality was 0.3% versus 0.5% (RR: 0.70, 95% CI: 0.36 to 1.33, p  0.27),
respectively.
Conclusions In the current era of elective PCI performed with stents and thienopyridines, GPIs provide clinical benefit. These
agents reduce nonfatal myocardial infarction without a notable increase in major bleeding; however, they in-
crease the risk of minor bleeding. All-cause mortality is not reduced. (J Am Coll Cardiol 2011;57:1190–9)
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.030Elective percutaneous coronary intervention (PCI) is com-
monly performed to relieve angina. The risks of PCI include
both thrombotic and bleeding events. Antiplatelet agents such
as aspirin, thienopyridines, and glycoprotein IIb/IIIa inhibitors
(GPIs) are available for use, as are antithrombin agents, which
include heparin and bivalirudin. Determining the optimal
regimen of adjunctive medications is critical to minimize
thrombotic events without increasing major bleeding.
Initial trials demonstrated that GPIs reduce myocardial
infarction (MI) and urgent revascularization after angioplasty
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accepted October 28, 2010.(1–3). Other advances, such as stents and thienopyridines, also
have become available that independently enhance the safety of
revascularization (4–9). Some modern trials and systematic
reviews, specifically in patients pre-treated with thienopyridines,
See page 1200
have failed to demonstrate the benefit of GPIs during elective
PCI (10–12). Thus, disagreement still exists about the optimal
use of GPIs during elective PCI (13,14). We hypothesized that
in elective PCI performed with coronary stents and thienopyri-
dines, GPIs will have minimal benefit and will increase the risk
of major bleeding.
Methods
Selection criteria. We selected studies that randomly assigned
patients undergoing elective PCI to a GPI versus control in which
the control could be: (1) placebo, or (2) usual care (without a GPI).
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studies routinely used coronary stents and periprocedural thien-
opyridines. We excluded trials in which 2 GPIs were compared
directly or in which the route of GPI administration was random-
ized (e.g., intracoronary versus intravenous).
Literature review. A computerized literature search of the
MEDLINE database was conducted without language restric-
tion from inception until February 2010 for randomized
clinical trials using the medical subject heading terms and
keywords listed in Figure 1. To increase sensitivity, we also
searched the references of other meta-analyses of GPIs, the
Cochrane clinical trials database, and ClinicalTrials.gov.
Outcomes and definitions. The coprimary outcomes of this
analysis were nonfatal MI, major bleeding, and all-cause
mortality. Additional outcomes included urgent revasculariza-
tion, stroke, minor bleeding, and thrombocytopenia. Nonfatal
MI was defined preferentially as 2 to 3 times the upper limit of
the normal range of the locally available creatine kinase-
myocardial band assay. If this definition was not available,
alternate definitions were included (described in the Results
section). Major and minor bleeding were defined preferentially
according to the Thrombolysis In Myocardial Infarction (TIMI)
criteria (TIMI major bleeding: intracranial hemorrhage or
clinically overt bleeding with drop in hemoglobin of 5 g/dl;
TIMI minor bleeding: clinically overt bleeding with drop in
hemoglobin of 3 to 5 g/dl). Similar to nonfatal MI, if a
TIMI definition for major bleeding was not available, alternate
definitions were included (described in Results). Urgent revas-
cularization was defined as ischemic symptoms that resulted in
an urgent need for repeat PCI or coronary artery bypass
grafting after the index procedure. Stroke was defined as total
stroke (ischemic and nonischemic). Thrombocytopenia was
defined as a platelet count after PCI of 100,000/mm3. All
outcomes were tabulated within 30 days, except for all-cause
mortality, which also was tabulated at 6 to 12 months.
Figure 1 Search Strategy
Flow diagram of the search terms used and the overall search strategy for this an
ACS  acute coronary syndrome; GPI  glycoprotein IIb/IIIa inhibitor; MeSH  meData extraction. Outcome data
were extracted independently by
2 authors (W.D.B. and K.E.P.),
and the information was recorded
on a standardized case report form.
Data about each trial’s baseline char-
acteristics, adjuvant medications,
definitions of clinical outcomes,
quality components, and duration or
completeness of follow-up were ex-
tracted. Data were entered into a
centralized database by a research
assistant, and discrepancies were re-
solved by consensus of 2 authors (D.E.W. and A.A.B.). Personal
communication with study authors was undertaken if additional
data or clarification were necessary. Native language-speaking
research associates were used when necessary for non-English
manuscripts.
Statistical analysis. Random effects summary risk ratios
(RRs) were constructed using a DerSimonian-Laird model.
Outcomes were assessed by grouping all trials together and
by stratifying according to GPI type (abciximab vs. small-
molecule GPI). Trial quality was assessed on the adequate
description of treatment allocation, blinded outcome assess-
ment, and description of losses to follow-up (15). We
assessed for publication bias by Begg and Mazumdar’s
method (16) and Egger’s method (17). Heterogeneity
between studies was assessed by calculating a Cochran’s
Q and an I2 statistic (18). We followed the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement for performing a high-
quality meta-analysis (19). We conducted sensitivity analy-
ses by restricting our investigation to placebo-controlled
trials and by using strict definitions of nonfatal MI and
major bleeding.
ubject heading.
Abbreviations
and Acronyms
CI  confidence interval
GPI  glycoprotein IIb/IIIa
inhibitor
MI  myocardial infarction
PCI  percutaneous
coronary intervention
RR  risk ratio
TIMI  Thrombolysis In
Myocardial Infarctionalysis.
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Study Name/First Author (Ref. #) Publication Year n Age (yrs) Female (%) DM (%) Prior MI (%) Stented (%)
3T/2R (21) 2009 263* 68/68 26/28 24/28 48/38 92/94
OPTIMIZE-IT (22) 2009 46 66/65 27/29 100/100 17/18 100/100
CLEAR PLATELETS-2 (23) 2009 200 65/64 34/41 34/39 32/26 100/100
De Luca et al. (24) 2008 132 63/63 41/35 100/100 11/14 100/100
Cuisset et al. (25) 2008 149* 66/64 25/23 35/40 NR 100/100
ASIAD (26) 2005 254 62/61 25/28 100/100 40/42 99/100
Prati et al. (27) 2005 140 62/62 17/17 21/11 NR 98/98
Kurowski et al. (28) 2005 50 69/67 16/16 24/16 72/72 100/100
De Luca et al. (29) 2005 122 61/64 30/40 100/100 13/11 100/100
CLEAR PLATELETS (30) 2005 120 61/62 33/47 38/42 27/28 93/93
Claeys et al. (31) 2005 200 69/65† 31/30 17/16 15/23 99/97
ISAR-SWEET (11) 2004 701 68/67 27/24 100/100 35/33 90/90
ISAR-SMART-2 (32) 2004 502 67/66 27/27 26/30 38/36 68/69
Okmen et al. (33) 2004 119 54/58 18/14 8/10 33/26 84/87
DANTE (34) 2004 96 59/61 47/55 100/100 67/33 100/100
ISAR-REACT (10) 2004 2,159 65/66 23/24 21/20 32/33 91/90
Juergens et al. (35) 2002 894 59/59 17/17 17/13 46/46 98/98
Tamburino et al. (36) 2002 107 61/63 13/12 28/27 65/69 100/100
TOPSTAR (37) 2002 96 64/66 26/24 20/26 42/35‡ 92/91
ESPRIT (38) 2001 2,064 62/62† 27/28 20/21 32/31 95/97
Galassi et al. (39) 1999 106 61/63 13/12 28/27 65/69 100/100
EPISTENT (40) 1998 1,603 59/59 25/26 20/21 50/55 97/96
All data are formatted as treatment/control and are reported as mean value unless noted otherwise. *Patients were selected for being poor responders to clopidogrel or aspirin. †Median age. ‡Defined
as recent MI.
ASIAD  Abciximab in Stenting Inhibits restenosis Among Diabetics; CLEAR PLATELETS  Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets; DANTE  Diabetes Abciximab
SteNT Evaluation; DM  diabetes mellitus; EPISTENT  Evaluation of Platelet IIb/IIIa Inhibitor for Stenting; ESPRIT  Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy;
ISAR-REACT  Intracoronary Stenting and Antithrombotic Regimen–Rapid Early Action for Coronary Treatment; ISAR-SMART  Intracoronary Stenting or Angioplasty for Restenosis in SMall
ARTeries; ISAR-SWEET  Intracoronary Stenting and Antithrombotic Regimen: is abciximab a Superior Way to Eliminate Elevated Thrombotic risk in diabetics; MI  myocardial infarction; NR 
not reported; OPTIMIZE-IT  OPtimal TIrofiban bolus to reduce post-PCI Myonecrosis and Improve coronary flow randomized Evalution In diabeTics; TOPSTAR  Troponin in planned PTCA/stent
implantation with or without administration of the glycoprotein IIb/IIIa Receptor Antagonist Tirofiban.Primary Study Outcomes and Individual Outcome DefinitionsTable 2 Primary Study Outcomes and Individual Outcome Definitions
Study Name/First Author (Ref. #) Primary Study Outcome
Definition of MI
(Multiples of ULN)
Definition of
Major Bleeding
Definition of
Thrombocytopenia
3T/2R (21) Periprocedural MI CK-MB 3 TIMI* NR†
OPTIMIZE-IT (22) Periprocedural MI Troponin I 3 Major hemorrhage NR
CLEAR PLATELETS-2 (23) Platelet reactivity CK-MB 3 TIMI NR
De Luca et al. 2008 (24) In segment late luminal loss CK-MB 3 TIMI NR
Cuisset et al. (25) Composite clinical outcomes Troponin I 1 TIMI NR
ASIAD (26) Angiographic restenosis CK-MB 3 TIMI NR
Prati et al. (27) Myocardial reperfusion CK-MB 2 NR NR
Kurowski et al. (28) Periprocedural MI Troponin I 1 NR NR
De Luca et al. 2005 (29) Target vessel revascularization NR NR NR
CLEAR PLATELETS (30) Platelet reactivity CK-MB 3 NR NR
Claeys et al. (31) Periprocedural MI CK-MB 3 3g/dl Hgb drop, ICH, or vascular repair 100,000/mm3
ISAR-SWEET (11) Composite clinical outcomes CK-MB 3 TIMI 20,000/mm3
ISAR-SMART-2 (32) Angiographic restenosis CK-MB 3 NR NR
Okmen et al. (33) Periprocedural MI CK-MB 2 NR NR
DANTE (34) In-stent percent volume obstruction CK-MB 3 NR NR
ISAR-REACT (10) Composite clinical outcomes CK-MB 3 TIMI 20,000/mm3
Juergens et al. (35) TIMI bleeding CK-MB 3 TIMI NR
Tamburino et al. (36) Composite clinical outcomes CK 3 TIMI 50,000/mm3
TOPSTAR (37) Periprocedural MI Troponin T 1 Transfusion NR†
ESPRIT (38) Composite clinical outcomes CK-MB 3 TIMI 20,000/mm3
Galassi et al. (39) Composite clinical outcomes CK 3 TIMI NR†
EPISTENT (40) Composite clinical outcomes CK or CK-MB 3 TIMI NR*TIMI major bleeding is defined as intracranial hemorrhage or clinically overt hemorrhage with drop in hemoglobin of 5 g/dl. †This outcome was reported but not defined.
CK-MB  creatine kinase-myocardial band; Hgb hemoglobin; ICH  intracranial hemorrhage; TIMI  Thrombolysis In Myocardial Infarction; ULN upper limit of normal; other abbreviations as in Table 1.
t
e
500 m
interve
1193JACC Vol. 57, No. 10, 2011 Winchester et al.
March 8, 2011:1190–9 Efficacy of Glycoprotein IIb/IIIa InhibitorsUnivariate meta-regression analysis was performed in an
attempt to explore for any modification of treatment effect
according to thienopyridine use after PCI versus before,
percentage of diabetics, publication year, and trials that used
a higher dose of heparin in the control arm versus a similar
dose between treatment arms (20). All statistical tests used
2-tailed p values with significance set at alpha  0.05 and
confidence intervals (CIs) calculated at the 95% level. All
analyses were performed using STATA software version 11
(STATA Corporation, College Station, Texas).
Results
Baseline characteristics. Our search identified 22 stud-
ies with 10,123 patients (Fig. 1, Table 1) (10,11,21– 40).
The studies examined a variety of clinical outcomes,
Study MedicationsTable 3 Study Medications
Study Name/First Author (Ref. #)
Type of
GPI
GPI Bolus
(g/kg)
GPI Infusion
(g/kg/min)
GPI
3T/2R (21) Tirofiban 25 0.15
OPTIMIZE-IT (22) Tirofiban 25 0.15
CLEAR PLATELETS-2 (23) Eptifibatide 180  2 2
De Luca et al. 2008 (24) Abciximab 0.25 0.125
Cuisset et al. (25) Abciximab 0.25 0.125
ASIAD (26) Abciximab 0.25 0.125
Prati et al. (27) Abciximab 0.25 10 g/min
Kurowski et al. (28) Tirofiban 10 0.15
De Luca et al. 2005 (29) Abciximab 0.25 0.125
CLEAR PLATELETS (30) Eptifibatide 180  2 2
Claeys et al. (31) Abciximab 0.25 10 g/min
ISAR-SWEET (11) Abciximab 0.25 0.125
ISAR-SMART-2 (32) Abciximab 0.25 0.125
Okmen et al. (33) Tirofiban 10 0.15
DANTE (34) Abciximab 0.25 0.125
ISAR-REACT (10) Abciximab 0.25 0.125
Juergens et al. (35) Tirofiban 10 0.1
Tamburino et al. (36) Abciximab 0.25 0.125
TOPSTAR (37) Tirofiban 10 0.15
ESPRIT (38) Eptifibatide 180  2 2
Galassi et al. (39) Abciximab 0.25 0.125
EPISTENT (40) Abciximab 0.25 0.125
In nonplacebo controlled trials, the control arm consisted of all therapies except the study drug. *
ACT  activated clotting time; GPI  glycoprotein IIb/III inhibitor; PCI  percutaneous coronaryincluding 7 that used a nonclinical primary outcome T(Table 2) (23,24,26,27,30,32,34). Details of GPI admin-
istration and adjuvant medications are listed in Table 3.
Trial dropout rates were low, and slightly more than half
of trials were placebo controlled (Table 4). One study was
not identified in the MEDLINE search because it was
missing the database label human and was located
through a hand search of references from other meta-
analyses (37,41).
Efficacy. Nonfatal MI at 30 days was reported for all but 2
trials (29,32). The incidence of MI was 5.1% with GPI and
8.3% with control (RR: 0.66, 95% CI: 0.55 to 0.79, p 
0.0001) (Fig. 2). Low heterogeneity was seen with this analysis
(I2  18.9%), and no publication bias was observed (Begg’s
est: p  0.39, Egger’s test: p  0.36). The magnitude of this
ffect was similar for both abciximab and small-molecule GPIs.
PCI
GPI in
Control Arm
(%) Thienopyridine Antithrombin Regimen
12 300 to 600 mg clopidogrel
before
UFH 50-70 U/kg with GPI vs.
100 U/kg with control
NR 300 mg clopidogrel
before*
UFH, dose not specified
NR 600 mg clopidogrel before Bivalirudin 0.75 mg/kg
0 300 mg clopidogrel before UFH, ACT 250 s
3 600 mg clopidogrel before UFH 50 U/kg with GPI vs.
70 U/kg with control
0 300 mg clopidogrel before UFH 50 U/kg with GPI vs.
70 U/kg with control
0 500 mg ticlopidine before UFH 70 to 100 U/kg
NR 300 mg clopidogrel before UFH 60 U/kg
0 300 mg clopidogrel after* UFH, ACT 250 s
NR 300 to 600 mg clopidogrel
after
UFH 60 U/kg
3 450 mg clopidogrel before UFH, ACT 200 s with GPI vs.
300 with control
0 600 mg clopidogrel before UFH 70 U/kg with GPI vs.
140 U/kg with control
NR 600 mg clopidogrel before UFH 70 U/kg with GPI vs.
140 U/kg with control
0 500 mg ticlopidine before UFH 70 U/kg with GPI vs.
10,000 U with control
0 500 mg ticlopidine before UFH 70 U/kg with GPI vs.
100 U/kg with control
NR 600 mg clopidogrel before UFH 70 U/kg with GPI vs.
140 U/kg with control
NR 75 mg clopidogrel daily
after*
UFH 100 U/kg
NR 500 mg ticlopidine before UFH 70 U/kg with GPI vs.
100 U/kg with control
NR 375 mg clopidogrel before UFH 5,000 to 10,000 U,
ACT 250 s
4 Loading dose before PCI† UFH 60 U/kg, ACT 200 to 300 s
2 500 mg ticlopidine before UFH 70 U/kg with GPI vs.
100 U/kg with control
10 500 mg ticlopidine before UFH 70 U/kg with GPI vs.
100 U/kg with control
g ticlopidine could be given in lieu of clopidogrel. †Dose not specified.
ntion; UFH  unfractionated heparin; other abbreviations as in Table 1.After
(h)
14–24
8
18
12
12
12
ND
12–14
12
18–24
12
12
12
24
12
12
36
12
18
18–24
12
12he results were unchanged when this analysis was restricted
p
c
u
0
r
1
(
t
O
i
d
S
(
w
t
1
0
w
(
a
G
p
D
O
s
S
o
n
b
m
a
E
ed out
1194 Winchester et al. JACC Vol. 57, No. 10, 2011
Efficacy of Glycoprotein IIb/IIIa Inhibitors March 8, 2011:1190–9to placebo-controlled trials (RR: 0.69, 95% CI: 0.55 to 0.86,
 0.001) and to trials that strictly defined MI based on
reatine kinase-myocardial band more than 2 to 3 times the
pper limit of normal of the local assay (RR: 0.70, 95% CI:
.53 to 0.93, p  0.013). Target vessel revascularization was
eported in 10 trials with incidence of 0.8% with GPI versus
.2% with control (RR: 0.71, 95% CI: 0.46 to 1.10, p 0.13)
10,11,23,24,26,34,35,38–40).
The logarithm of RR for nonfatal MI plotted against publica-
ion year did not reveal any effect modification (p 0.99) (Fig. 3).
ther potential modifiers that were examined by metaregression
ncluded: thienopyridine use after versus before PCI (p  0.99),
high percentage of diabetic patients (p 0.61), and use of a higher
ose of heparin in the control arm (p  0.78).
afety. Major bleeding was reported in all but 7 trials
27–30,32–34). The incidence of major bleeding was 1.2%
ith GPI versus 0.9% with control (RR: 1.37, 95% CI: 0.83
o 2.25, p  0.22) (Fig. 4). Heterogeneity was low (I2 
6.2%), and publication bias was not found (Begg’s test: p
.71, Egger’s test: p  0.91). Results were not different
hen the analysis was restricted to placebo-controlled trials
RR: 1.17, 95% CI: 0.70 to 1.93, p  0.55) or to trials that
strictly reported TIMI major bleeding (RR: 1.28, 95% CI:
0.71 to 2.32, p  0.41). Incidence of minor bleeding was
3.0% versus 1.7% with control (RR: 1.70, 95% CI: 1.28 to
2.26, p  0.0001). Based on 8 trials, the incidence of
thrombocytopenia was 0.8% with GPI versus 0.04% with
Study QualityTable 4 Study Quality
Study Name/First Author (Ref. #)
Generation o
Treatment Assign
3T/2R (21) Sealed envelope
OPTIMIZE-IT (22) Computer generat
CLEAR PLATELETS-2 (23) Computer generat
De Luca et al. 2008 (24) Not described
Cuisset et al. (25) Telephone generat
ASIAD (26) Computer generat
Prati et al. (27) Not described
Kurowski et al. (28) Not described
De Luca et al. 2005 (29) Not described
CLEAR PLATELETS (30) Computer generat
Claeys et al. (31) Not described
ISAR-SWEET (11) Sealed envelope
ISAR-SMART-2 (32) Computer generat
Okmen et al. (33) Not described
DANTE (34) Sealed envelope
ISAR-REACT (10) Sealed envelope
Juergens et al. (35) Not described
Tamburino et al. (36) Sealed envelope
TOPSTAR (37) Independent study
ESPRIT (38) Not described
Galassi et al. (39) Random number
EPISTENT (40) Telephone generat
Data are presented as treatment/control. *Diagnostic studies review
†Double-blind trial; however, no specific mention of independent blind
Abbreviations as in Table 1.control (RR: 4.77, 95% CI: 1.67 to 13.64, p  0.004) d(10,11,21,31,36–39). The risk of thrombocytopenia signif-
icantly increased with abciximab (RR: 6.91, 95% CI: 1.80 to
26.46, p  0.005), in contrast to small-molecule GPIs (RR:
2.65, 95% CI: 0.49 to 14.34, p 0.26). Stroke was reported
in 5 trials, with an incidence of 0.2% with GPI and of 0.09%
with control (RR: 3.01, 95% CI: 0.61 to 14.87, p  0.18)
(30,35,37,38,40).
All-cause mortality. Mortality within 30 days was 0.3% with
GPI versus 0.5% with control (RR: 0.70, 95% CI: 0.36 to 1.33,
p  0.27) (Fig. 5). There was no evidence for heterogeneity
(I2  0%) or publication bias (Begg’s test: p  0.99, Egger’s
test: p  0.91). Data for mortality at 6 to 12 months were
vailable for 8,480 patients with an incidence of 2.9% with
PI versus 3.3% with control (RR: 0.88, 95% CI: 0.66 to 1.18,
 0.41).
iscussion
ur analysis of 22 studies with 10,123 patients demon-
trates that GPIs are beneficial during contemporary PCI.
pecifically, the addition of a GPI during stent-based PCI
n a background of aspirin and a thienopyridine reduces
onfatal MI without an appreciable increase in major
leeding; however, minor bleeding is increased. All-cause
ortality is not reduced. Findings were similar between
bciximab and the small-molecule GPIs.
xploring heterogeneity. There was a small degree of
Independent Blinded
Outcome Assessment
Placebo
Controlled
Dropout
(%)
Yes Yes 0/0
No* Yes 8.3/0
Yes No NR/NR
Yes† Yes 3/3‡
No No 0/0
Yes† Yes 3.1/0
No* No 5.7/0
No No 0/0
Yes† Yes 0/0
No No NR/NR
No No 0/0
Yes Yes 3.1/3.7
Yes Yes NR/NR
No No 0/0
No* No 0/0
Yes Yes 0/0
Yes Yes NR/NR
No* No 0/0
Yes† Yes NR/NR
Yes Yes 0.1/0.1
No* No NR/NR
Yes Yes 1/1.2
linded fashion. No mention of blinded clinical outcome assessment.
come assessment. ‡Overall percentage of drop-outs over 6 months.f
ment
ed
ed
ed
ed
ed
ed
nurse
ed
ed in bispersion (heterogeneity) around the nonfatal MI sum-
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March 8, 2011:1190–9 Efficacy of Glycoprotein IIb/IIIa Inhibitorsmary estimate; however, the reduction in nonfatal MI
was reduced to a similar magnitude with abciximab and
the small-molecule GPIs. This class-effect finding is in
contradistinction to the TARGET (Do Tirofiban and
ReoPro Give Similar Efficacy Trial), which documented
the superiority of abciximab compared with tirofiban (42).
Our selected studies spanned more than a decade, during
which time significant refinements in catheters, wires,
balloons, and stents took place that have contributed to the
current safety of PCI. This was the motivation for perform-
ing metaregression as a function of publication year, al-
though the most recent studies seemed to have the same
degree of benefit from GPIs as the earlier studies. Addi-
tionally, no effect modification was found by examining
studies with a large proportion of diabetics or studies that
used a relatively high dose of heparin in the control arm
(versus similar dose between treatment arms).
Balancing adverse thrombotic and bleeding events. El-
evation of postprocedural cardiac enzymes occurred in
8.3% of control patients. The degree of cardiac enzyme
elevation has been associated, in a dose-dependent fash-
ion, with an increased risk for long-term mortality
Figure 2 RRs for Nonfatal Myocardial Infarction
Trials that did not report nonfatal myocardial infarction were excluded from this analysis. T
Stenting Inhibits restenosis Among Diabetics; CI  confidence interval; CLEAR PLATELETS
ation of Platelet IIb/IIa Inhibitor for Stenting; ESPRIT  Enhanced Suppression of the Plate
Intracoronary Stenting and Antithrombotic Regimen–Rapid Early Action for Coronary Treatm
rior Way to Eliminate Elevated Thrombotic risk in diabetics; OPTIMIZE-IT  OPtimal TIrofiba
diabeTics; RR  risk ratio; TOPSTAR  Troponin in planned PTCA/stent implantation withhe size of the data markers indicates the relative weight of each study. ASIAD  Abciximab in
 Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets; EPISTENT  Evalu-
let IIb/IIIa Receptor with Integrilin Therapy; GPI  glycoprotein IIb/IIIa inhibitor; ISAR-REACT 
ent; ISAR-SWEET  Intracoronary Stenting and Antithrombotic Regimen: is abciximab a Supe-
n bolus to reduce post-PCI Myonecrosis and Improve coronary flow randomized Evaluation In
or without administration of the glycoprotein IIb/IIIa Receptor Antagonist Tirofiban.(43,44). Our analysis demonstrates that using GPIsFigure 3 Metaregression Plot
Plot of univariate metaregression examining the effect of publication year on
the relationship between glycoprotein inhibitors and nonfatal myocardial infarc-
tion (MI) (p  0.99). Trials that did not report nonfatal myocardial infarction
were excluded. The area of each circle is inversely proportional to the variance
of the estimate of the log risk ratio. RR  risk ratio.
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MI by approximately 30%.
We found that the risk of major bleeding was nonsignifi-
cantly increased, although minor bleeding was increased by
approximately 70% with GPIs. Major bleeding increases the
risk for long-term mortality (45,46); however, even a minor
bleed, similar to a small post-procedural MI, can worsen long-
term prognosis (45). Although we did not find that GPIs
increase major bleeding, their use in acute coronary syndromes
may potentiate this hazard (47).We did not expect to find a
difference in short-term mortality from GPI use because of the
low-risk nature of the studied patients. Had major bleeding
occurred more frequently than nonfatal MI, there might have
been a signal for increased all-cause mortality.
Clinical use and future directions. Our results are largely
applicable to patients pre-treated with thienopyridines,
because this group represented approximately 94% of the
weight of the nonfatal MI outcome. Despite the benefit of
clopidogrel pre-treatment (48,49), some practitioners may
choose to give this medication after coronary angiography
has been performed in case coronary artery bypass grafting
is needed. GPIs may obviate the need for clopidogrel
pre-treatment; however, this approach is not supported by
our findings and deserves further study.
Current guidelines state that the use of a GPI is
Figure 4 RRs for Major Bleeding
Trials that did not report major bleeding were excluded from this analysis. The size ofrecommended as a Class IIa agent (Level of Evidence: B)(13). The European Society of Cardiology guidelines also
endorse GPIs as a Class IIa agent (Level of Evidence: C),
but only in bailout situations (14). We believe our
analysis supports and potentially expands the use of GPIs
in appropriate clinical situations.
Further approaches that may be used to enhance the
benefit of GPIs while minimizing their risk include the
following: intracoronary versus intravenous administration
(50), abbreviated infusion (51), and preferential use in
patients resistant to thienopyridines (21,25). Lastly, the role
of GPIs will need to be reappraised as newer and more
potent agents become available (52–54).
Study strengths. We believe our rigorous search strategy
has resulted in the most comprehensive review to date of
GPI use during elective PCI. We used multiple layers of
data verification and sensitivity analyses, which add strength
to our meta-analysis. As previously described, this analysis
had no publication bias and the level of heterogeneity was
low. Also, metaregression was unable to uncover any subtle
sources of effect modification.
Study limitations. We were not able to analyze our results by
lesion complexity; response to aspirin, clopidogrel, or both; or
baseline use of statins, which recently were shown to reduce
postprocedural MI (55). Some of the included trials were open
label, which might have introduced bias; however, our findings
ta markers indicates the relative weight of each study. Abbreviations as in Figure 2.the dawere unchanged after sensitivity analysis with restriction to
1197JACC Vol. 57, No. 10, 2011 Winchester et al.
March 8, 2011:1190–9 Efficacy of Glycoprotein IIb/IIIa Inhibitorsplacebo-controlled trials. These also were the trials that had
independent blinded outcome assessment with low participant
dropout, thus indicating studies of high quality. We included
studies that used ticlopidine; however, because the clinical
efficacy of this agent is considered similar to that of clopidogrel,
we considered this a reasonable approach (56).
Conclusions
In the current era of elective PCI performed with stents and
thienopyridines, GPIs reduce nonfatal MI without a notable
increase in major bleeding. However, these agents increase minor
bleeding and thrombocytopenia. Overall, the use of GPIs during
elective modern PCI seems to be safe and effective.
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